SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are experiencing a sharp sell-off despite delivering a strong earnings beat and raising guidance, as the market reacts to management's comments regarding volatile search referral traffic and concerns over future user growth. Community members are actively debating whether this decline represents a short-term liquidity flush and a prime buying opportunity, or if the stock faces deeper issues related to platform moderation and potential long-term dependency on Google for user acquisition.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is currently trending as investors focus on its monthly dividend income and potential for share price recovery as it navigates market volatility. The community remains active in discussing optimal income-generating portfolio strategies, often comparing the fund to peers like QQQI and JEPI to balance growth exposure with sustainable monthly cash flow.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is currently a focal point for investors due to intensifying speculation regarding potential acquisition interest and the evolving landscape of autonomous vehicle partnerships. The community is actively debating the company's valuation against its ride-hailing peers, with significant attention on its high short interest and strategic moves to expand its footprint in both domestic and international markets.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is under heavy scrutiny following a late-stage heart drug trial failure, fueling intense community debate over its R&D pipeline and competitive positioning against Eli Lilly. While some investors are treating the resulting sell-off as an overreaction and a buying opportunity, others are questioning management's long-term strategy and execution beyond their GLP-1 success.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining traction as investors focus on its role in rugged edge AI and defense infrastructure, with recent activity fueled by a new production order and anticipation of future U.S. Army situational awareness contracts. The community is closely monitoring institutional accumulation and potential index-related inflows while debating the impact of macro-market volatility on this small-cap hardware developer.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors monitor ongoing legal battles over GLP-1 marketing claims while anticipating significant growth from its obesity and diabetes drug franchise. The market is also buzzing about a potential acquisition of psychedelic drugmaker AtaiBeckley, signaling Lilly's aggressive strategy to expand its neuroscience pipeline beyond its current pharmaceutical leaders.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently trending as investors weigh federal support from the Trump administration's initiative to fast-track nuclear reactors for AI data centers against persistent concerns over the company's lack of revenue and the frequency of insider share sales. While bullish participants point to these government partnerships as a path toward commercialization and future criticality, skeptical traders remain focused on the stock's significant decline from previous highs and the lack of a proven power generation track record.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors weigh an upcoming EMA decision on Yartemlea against its U.S. commercial ramp, with the community actively discussing potential short squeezes and the impact of recent debt repurchases on the company's valuation. Market participants are divided between skepticism regarding management's communication and optimism over key catalysts like Medicare's New Technology Add-On Payment status.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing increased volatility as investors weigh the appointment of a new board member focused on commercialization against concerns over potential future dilution and sustained short selling pressure. While the community remains divided over management's strategic direction, the upcoming maintenance data readout is being closely watched as a critical catalyst for the obesity pipeline's long-term valuation.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following positive institutional developments, including a recent record-breaking auto ABS deal and significant insider purchasing from the CEO, which have bolstered investor confidence. The community is actively discussing a potential re-rating of the stock as it shows resilience despite broader fintech volatility, with many participants pointing to strong quarterly fundamentals and ongoing analyst upgrades as catalysts for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oversold Conditions For Lenz Therapeutics (LENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HC Wainwright Expects Weaker Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for LENZ Therapeutics in a research note issued to investors on Tuesday, April...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm...

LENZ Therapeutics (NASDAQ:LENZ) Price Target Cut to $48.00 by Analysts at HC Wainwright

HC Wainwright reduced their target price on LENZ Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday...

Aberdeen Group plc Increases Holdings in LENZ Therapeutics, Inc. $LENZ

Aberdeen Group plc lifted its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 274.4% during the fourth quarter, according to the company in its most recent filing with...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One...

HC Wainwright Issues Positive Forecast for LENZ Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for LENZ Therapeutics in a report issued on...

$LENZ Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.32 down -149.06% YoY
• Reported revenue of $1.9M
• LENZ Therapeutics believes its existing cash, cash equivalents, and marketable securities of $258.4M as of March 31, 2026, are sufficient to fund operations for at least the next 12 months and reach positive operating cash flow.

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

LENZLENZ Therapeutics Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest LENZ News